Results 51 to 60 of about 2,821 (202)

The Benefits of Adding Non‐Antimuscarinic Pharmaceuticals in Combination With Beta‐3 Agonists for Overactive Bladder Treatment: A Systematic Review

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Antimuscarinics, as the current first‐line pharmacologic therapies for overactive bladder, exhibit low patient adherence and high rates of reported side effects. As a modern alternative pharmaceutical treatment, beta‐3 agonists, which relax the urinary bladder, may be more tolerable for patients, increasing adherence and ...
Felicity Smith, Charlotte Phelps, Christian Moro   +2 more
wiley   +1 more source

Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study

Research and Reports in Urology, 2020
Jörg Krebs,1 Jürgen Pannek,2,3 Franziska Rademacher,2 Jens Wöllner2 1Clinical Trial Unit, Swiss Paraplegic Centre, Nottwil, Switzerland; 2Neuro-Urology, Swiss Paraplegic Centre, Nottwil, Switzerland; 3Department of Urology, Inselspital ...
Krebs J, Pannek J, Rademacher F, Wöllner J   +3 more
doaj  

Patterns of use of medications used to treat urinary incontinence and potentially inappropriate prescriptions

Therapeutic Advances in Urology, 2023
Background: The pharmacological treatment of urinary incontinence (UI) may involve bladder antimuscarinics, which can generate risks in the elderly. Objective: The aim was to determine the treatment patterns of a group of patients with UI and possible ...
Luis Fernando Valladales-Restrepo, Hugo Alejandro Bedoya-Arias, Brayan Stiven Aristizábal-Carmona, Jorge Enrique Machado-Alba   +3 more
doaj   +1 more source

Investigation of the mechanisms and modulation of irinotecan‐induced emesis in Suncus murinus

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Irinotecan is a widely used chemotherapeutic agent that frequently causes nausea and emesis. Its emetic mechanism of action is poorly understood and the choice of drugs to reduce nausea and emesis is largely empirical. Experimental Approach Using Suncus murinus, we examined (i) the dose–response and temporal profile of ...
Zengbing Lu, Julia Y. H. Liu, Yasuhiro Nakagami, Zitong Li, Xiaofei Huang, Man P. Ngan, Dexuan Cui, John A. Rudd   +7 more
wiley   +1 more source

Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives

International Journal of Women's Health, 2023
Dudley Robinson, Miriam O’Kane, Linda Cardozo Department of Urogynaecology, King’s College Hospital, London, UKCorrespondence: Dudley Robinson, Department of Urogynaecology, King’s College Hospital, Suite 8, Level 3, Golden Jubilee Wing, London, SE5 9RS,
Robinson D, O'Kane M, Cardozo L
doaj  

Mirabegron: pharmacoeconomic aspects of the use of the drug for the treatment of overactive bladder syndrome

Качественная клиническая практика, 2022
According to the International Continence Society (ICS), symptoms of overactive bladder (OAB) are present in 17 % of the adult population of Europe.
O. I. Ivakhnenko, E. V. Derkach, V. S. Krysanova, A. D. Ermolaeva, K. A. Kokushkin   +4 more
doaj   +1 more source

Annual trend in prescriptions of antimuscarinics calculated by defined daily dose (DDD) for the treatment of LUTS in women, 2007–2012.

, 2019
The black line is the overall DDD of antimuscarinics for each year. The dotted line is the trendline of linear regression test.
Ling-Ying Wu (7470542), Chi-Chih Chang (7470536), Kuo-How Huang (177500), Wei-Yi Huang (314061), Yu-Hua Lin (4449001), Yu-Fen Chen (7470539), Hong-Chiang Chang (445134)   +6 more
core   +1 more source

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder:Findings from a Non-Interventional, Multinational, Cohort Study [PDF]

, 2021
Introduction: During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased vital signs vs placebo in patients with overactive bladder.
Horter, Libby, de Vogel, Stefan, Olesen, Morten; id_orcid, Seeger, John D., Hoffman, Veena, Phiri, Kelesitse, Xu, Yihua, Hallas, Jesper, Suehs, Brandon T., Arana, Alejandro, Perez-Gutthann, Susana, Enger, Cheryl, Appenteng, Kwame, Linder, Marie, Odsbu, Ingvild, Kristiansen, Nina Sahlertz, Margulis, Andrea, Phiri, K, Horter, L, Margulis, AV, Enger, C, Hallas, J, Odsbu, I,, Linder, M,, Arana, A, Suehs, BT, Hoffman, V   +26 more
core   +1 more source

Impact of COVID‐19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1692-1700, November 2026.
ABSTRACT Aims To evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID‐19, and to assess associations with comorbidities, disease severity, and vaccination status. Methods We conducted a prospective cohort study of adult patients hospitalized with confirmed COVID‐19, who ...
Julia Duarte de Souza, Jose de Bessa Jr., Natássia Cristina Carboni Truzzi, Carolina Trigo Rocha, Bruno Camargo Rocha Paim de Araujo, Julyana Kanate Mazzoni Moromizato, Thulio Bosi Vieira Brandão, Rachel Mazoni Costa, Marcelo Hisano, Zein Mohamed Sammour, Homero Bruschini, William Carlos Nahas, Cristiano Mendes Gomes   +12 more
wiley   +1 more source

Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States

Journal of International Medical Research, 2022
Objective To understand factors guiding overactive bladder (OAB) therapy selection and experience with combination therapy (antimuscarinics and beta-3 agonists).
Stephen R. Kraus, Junlong Li, Rita M. Kristy, Amy Lockefeer, Hongbo Yang, Mo Zhou, David R. Walker   +6 more
doaj   +1 more source